| Methods |
4‐week single‐blind placebo washout; inclusion criteria= supine DBP 95‐115 mm Hg after washout; 6‐week double‐blind treatment |
| Participants |
Lisinopril 1.25 mg: n=41(38 males,3 females); mean age=58 years; baseline BP not reported for all randomized patients;
Lisinopril 5 mg: n=41(37 males,4 females); mean age=56 years; baseline BP not reported for all randomized patients;
Lisinopril 20 mg: n=44(42 males,2 females); mean age=54 years; baseline BP not reported for all randomized patients;
Lisinopril 80 mg: n=43(37 males,6 females); mean age=57 years; baseline BP not reported for all randomized patients;
Placebo: n=47(40 males,7 females); mean age=56 years; baseline BP not reported for all randomized patients |
| Interventions |
Lisinopril 1.25 mg once daily;
Lisinopril 5 mg once daily;
Lisinopril 20 mg once daily
Lisinopril 80 mg once daily (patients received 40 mg once daily for the first 2 weeks and then 80 mg once daily for the last 4 weeks);
Placebo;
administered at 9 AM |
| Outcomes |
Trough erect SBP/DBP using mercury sphygmomanometer;
Trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and 95% CI reported, endpoint BP reported, endpoint SD not reported; calculated SD of change from 95% CI; erect BP data from Table 3, p. 418; supine BP data from Table 2, p. 417; Jadad score=3; funding source= Merck Sharp & Dohme |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
